(28 days)
Not Found
No
The description focuses on the mechanical and control aspects of a cryosurgical system, with no mention of AI or ML for image analysis, decision support, or any other function. The software mentioned manages basic system functions like pressure, timing, and data, which is typical for medical devices and does not imply AI/ML.
Yes.
The device is specifically indicated for 'cryogenic destruction of tissue' and to 'ablate benign and malignant lesions' using cryosurgery, which are therapeutic actions.
No
The device is described as a cryosurgical tool used for the destruction/ablation of tissue, not for diagnosing conditions.
No
The device description clearly outlines hardware components including a console with a touch panel computer, cryogen, suction, and electronics modules, a mobile cart, foot pedals, a fill kit, safety features like pressure relief valves and an emergency stop button, and disposable spray kits with catheters and introducers. While software is mentioned as managing functions, it is integral to the operation of the physical hardware system.
Based on the provided information, the truFreeze System is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use is for the "cryogenic destruction of tissue" and "to ablate benign and malignant lesions." This describes a surgical procedure performed directly on the patient's body.
- Device Description: The device description details a system that applies liquid nitrogen to tissue via a catheter. This is a physical intervention on the patient.
- Lack of IVD Characteristics: There is no mention of the device being used to examine specimens (like blood, urine, or tissue samples) outside of the body to provide information for diagnosis, monitoring, or screening.
IVD devices are used to perform tests on samples taken from the human body to provide information about a person's health. The truFreeze System is a therapeutic device used for tissue ablation.
N/A
Intended Use / Indications for Use
The truFreeze System is intended for cryogenic destruction of tissue using Liquid Nitrogen spray that has a boiling point of -196ºC requiring either active or passive venting during surgical procedures.
The truFreeze System is indicated for use as a cryosurgical tool in the fields of dermatology, and general surgery, to ablate benign and malignant lesions.
Product codes (comma separated list FDA assigned to the subject device)
GEH
Device Description
The trulFreeze system is a cryosurgical tool that applies medical-grade liquid nitrogen to the ablation area via a small, low pressure, open tipped catheter. The truFreeze System consists of a console and a disposable spray kit.
Console:
There are no proposed changes to the console is the central interface of the system and is comprised of a touch panel computer (TPC) and cryogen, suction, and electronics modules packaged in a mobile cart. Users interact with the console through a dual foot pedal and a touch panel. An off-the-shelf controller and associated software manage the cryogen level sensing, filling, pressure, cooling, defrost, suction, timing and data management functions. A fill kit, stored on the rear of the console, allows for liquid nitrogen transfer from the source tank to the console. Safety features include indicators, tank pressure relief valves, an isolated low voltage power system, and an emergency stop button to be used in the event of user or technical malfunction.
Disposable spray kit:
There are 2 types of spray kits available. One kit is available for active venting procedures and one is available for passive venting procedures. Both active and passive venting kits are provided in a carton of five (5) individually packaged sterile, single-use catheters with introducers in individual pouches. Additionally, the active venting kit is provided with a carton of five (5) individually packaged sterile. single-use CDTs with associated tubing in individual pouches. Each carton within a spray kit contains the instructions for use. There is a proposed change to the active venting disposable spray kit. The proposed change reduces the Outside Diameter (OD) of the CDT from 20 French to 16 French without changing performance specifications, adds additional Marker Bands to the 16 French version of the CDT and makes the 16 Fr CDT and 20 Fr CDT available as a 5-pack box in addition to as a part of the active venting kit.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The truFreeze System was previously subjected to a comprehensive test program that included electrical safety and electromagnetic compatibility test, software tests, animal testing, biocompatibility and sterilization testing. The proposed modifications do not require repeating these tests.
The proposed reduction in CDT OD and addition of Marker Bands were subjected to CSA's verification and validation testing processes.
Summary of Test Results:
Proposed Change: Reduce CDT OD
Test Specification: The CDT shall be less than or equal to 16.5 Fr. Result: Pass.
Test Specification: The CDT shall not crack, break or experience lumen separation after exposure to temperatures with the boundary range of - 196°C and 40°C. Result: Pass.
Test Specification: Shall have sufficient column strength to allow it to be advanced over a 0.072” Savary Wire. Result: Pass.
Test Specification: Shall maintain structural integrity and not kink while looped in a minimum internal bend radius. Result: Pass.
Test Specification: A complete flex of the CDT shall meet current kinking specification. Result: Pass.
Test Specification: The bonded CDT connector will withstand a minimum of 10lbf pull force without failing. Result: Pass.
Test Specification: Flow Rate shall meet current specification. Result: Pass.
Test Specification: The CDT OD shall not deform per specification. Result: Pass.
Test Specification: The bonded CDT connector will shall meet current. pull force specification without failing. Result: Pass.
Proposed Change: Enhance Visualization
Test Specification: Circumferential banding must be sufficient to identify the banding through an endoscope. Result: Pass.
Test Specification: Shall be labeled with four side-by-side 0.100"±0.030" wide identifying bands 7.7" ±0.1" from the distal end. Result: Pass.
Test Specification: All 0.100" wide bands shall be 360 degrees. Result: Pass.
Summary of Design Validation Testing Completed:
Proposed Change: Reduce CDT OD
Test Specification: CDT diameter will be as small as possible while enabling gas egress and allowing it to pass through the majority of anatomies with and without dilation. Result: Pass. Protocol Report: PRO-R-17-00193 User Survey / Simulated Use, PRO-R-17-00198 Animal Study.
Proposed Change: Enhance Visualization
Test Specification: CDT will have Mark Bands to assist user for performing the initial, approximate placement of the CDT. Result: Pass. Protocol Report: PRO-R-17-00193 User Survey / Simulated Use.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 878.4350 Cryosurgical unit and accessories.
(a)
Identification —(1)Cryosurgical unit with a liquid nitrogen cooled cryoprobe and accessories. A cryosurgical unit with a liquid nitrogen cooled cryoprobe and accessories is a device intended to destroy tissue during surgical procedures by applying extreme cold.(2)
Cryosurgical unit with a nitrous oxide cooled cryoprobe and accessories. A cryosurgical unit with a nitrous oxide cooled cryoprobe and accessories is a device intended to destroy tissue during surgical procedures, including urological applications, by applying extreme cold.(3)
Cryosurgical unit with a carbon dioxide cooled cryoprobe or a carbon dioxide dry ice applicator and accessories. A cryosurgical unit with a carbon dioxide cooled cryoprobe or a carbon dioxide dry ice applicator and accessories is a device intended to destroy tissue during surgical procedures by applying extreme cold. The device is intended to treat disease conditions such as tumors, skin cancers, acne scars, or hemangiomas (benign tumors consisting of newly formed blood vessels) and various benign or malignant gynecological conditions affecting vulvar, vaginal, or cervical tissue. The device is not intended for urological applications.(b)
Classification. Class II.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized representation of a human figure in profile, with three overlapping heads suggesting a sense of community and connection. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the figure.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
October 25, 2016
CSA Medical Incorporated Ms. Sherrie Coval-Goldsmith Vice President of Regulatory Affairs & Quality Assurance 91 Hartwell Avenue Lexington, Massachusetts 02421
Re: K162695
Trade/Device Name: truFreeze System Regulation Number: 21 CFR 878.4350 Regulation Name: Cryosurgical Unit and Accessories Regulatory Class: Class II Product Code: GEH Dated: September 27, 2016 Received: September 29, 2016
Dear Ms. Coval-Goldsmith:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours, Jennifer R. Stevenson -A
For Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known)
Device Name truFreeze® System
Indications for Use (Describe)
Intended Use
The truFreeze System is intended for cryogenic destruction of tissue using Liquid Nitrogen spray that has a boiling point of -196ºC requiring either active or passive venting during surgical procedures.
Indications for Use
The truFreeze System is indicated for use as a cryosurgical tool in the fields of dermatology, and general surgery, to ablate benign and malignant lesions.
Type of Use (Select one or both, as applicable)
2 Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
FORM FDA 3881 (1/14)
EF PSC Publishing Services (301) 443-6740
3
510(k) Summary (truFreeze® System)
Applicant Establishment Registration Number Contact Person
Summary Date Proprietary Name Classification Classification Name Regulation Number Classification Predicate Device
CSA Medical 3004534508 Sherrie Coval-Goldsmith, M.S. Vice President RA/QA CSA Medical 91 Hartwell Ave Lexington, Ma 02421 Phone: 781-538-7447 Fax: 781-538-4730 sgoldsmith@csamedical.com 26 September 2016 truFreeze® System Class II Cryosurgical Unit, Cryogenic Surgical Device 21 CFR 878.4350 Product Code GEH K161557 (truFreeze System)
Device Description
The truFreeze system is a cryosurgical tool that applies medical-grade liquid nitrogen to the ablation area via a small, low pressure, open tipped catheter. The truFreeze System consists of a console and a disposable spray kit.
Console:
There are no proposed changes to the console is the central interface of the system and is comprised of a touch panel computer (TPC) and cryogen, suction, and electronics modules packaged in a mobile cart. Users interact with the console through a dual foot pedal and a touch panel. An off-the-shelf controller and associated software manage the cryogen level sensing, filling, pressure, cooling, defrost, suction, timing and data management functions. A fill kit, stored on the rear of the console, allows for liquid nitrogen transfer from the source tank to the console. Safety features include indicators, tank pressure relief valves, an isolated low voltage power system, and an emergency stop button to be used in the event of user or technical malfunction.
Disposable spray kit:
There are 2 types of spray kits available. One kit is available for active venting procedures and one is available for passive venting procedures. Both active and passive venting kits are provided in a carton of five (5) individually packaged sterile, single-use catheters with introducers in individual pouches. Additionally, the active venting kit is provided with a carton of five (5) individually packaged sterile. single-use CDTs with associated tubing in individual pouches. Each carton within a spray kit contains the instructions for use. There is a proposed change to the active venting disposable spray kit. The proposed change reduces the Outside Diameter (OD) of the CDT from 20 French to 16 French without changing performance specifications, adds additional Marker Bands to the 16 French version of the CDT and makes the 16 Fr CDT and 20 Fr CDT available as a 5-pack box in addition to as a part of the active venting kit.
Intended Use/Indications for Use and Instructions for Use
The truFreeze System is identical in its Intended Use and Indication for Use as the predicate device (K161557 truFreeze system).
Both the predicate device and the proposed device are intended for cryogenic destruction of tissue using Liquid Nitrogen spray that has a boiling point of -196°C requiring either active or passive venting during surgical procedures.
4
Both the predicate device and the proposed device are indicated for use as a cryosurgical tool in the fields of dermatology, gynecology, and general surgery, to ablate benign and malignant lesions.
These are the same Intended Use and Indication for Use as the previously cleared version of the trulFreeze System (K161557).
The Instructions for Use and the Operator's Manual require modification to reflect the availability of a 16 Fr OD CDT and the addition of two (2) Marker Bands to the 16 Fr CDT.
Technical and Operational Characteristics
The truFreeze System is similar in design, hardware and software, as well as operational and technological characteristics as the predicate device. No new safety concerns are being raised by the reduction in the CDT OD, additional Marker Bands or 5-Pack Configurations.
Testing
The truFreeze System was previously subjected to a comprehensive test program that included electrical safety and electromagnetic compatibility test, software tests, animal testing, biocompatibility and sterilization testing. The proposed modifications do not require repeating these tests.
The proposed reduction in CDT OD and addition of Marker Bands were subjected to CSA's verification and validation testing processes.
| Proposed Change | Test Specification | Result |
|---|---|---|
| Reduce CDT OD | The CDT shall be less than or equal to 16.5 Fr | Pass |
| The CDT shall not crack, break or experience lumen separation after exposure to temperatures with the boundary range of - 196°C and 40°C. | Pass | |
| Shall have sufficient column strength to allow it to be advanced over a 0.072” Savary Wire | Pass | |
| Shall maintain structural integrity and not kink while looped in a minimum internal bend radius. | Pass | |
| A complete flex of the CDT shall meet current kinking specification. | Pass | |
| The bonded CDT connector will withstand a minimum of 10lbf pull force without failing. | Pass | |
| Flow Rate shall meet current specification. | Pass | |
| The CDT OD shall not deform per specification. | Pass | |
| The bonded CDT connector will shall meet current. pull force specification without failing | Pass | |
| Enhance Visualization | Circumferential banding must be sufficient to identify the banding through an endoscope. | Pass |
| Shall be labeled with four side-by-side 0.100"±0.030" wide identifying bands 7.7" ±0.1" from the distal end. | Pass | |
| All 0.100" wide bands shall be 360 degrees | Pass |
Table 1. Summary of Test Results
5
| Summary of Design Validation Testing Completed | |||
|---|---|---|---|
| Proposed Change | Test Specification | Result | Protocol Report |
| Reduce CDT OD | CDT diameter will be | ||
| as small as possible | |||
| while enabling gas | |||
| egress and allowing | |||
| it to pass through | |||
| the majority of | |||
| anatomies with and | |||
| without dilation | Pass | PRO-R-17-00193 User Survey / | |
| Simulated Use | |||
| PRO-R-17-00198 Animal Study | |||
| Enhance | |||
| Visualization | CDT will have Mark | ||
| Bands to assist user | |||
| for performing the | |||
| initial, approximate | |||
| placement of the | |||
| CDT | Pass | PRO-R-17-00193 User Survey / | |
| Simulated Use |
Rationale For Substantial Equivalence
The proposed changes do not affect the Indications for Use of the truFreeze System or alter the fundamental scientific technology of the device compared with the predicate device. They do not introduce any new safety or efficacy questions.
The company, through its design control activities, has determined that clinical data are not necessary to evaluate safety and effectiveness related to this change and that the results of design validation do not raise new issues of Safety or Effectiveness. Consequently, in the opinion of the company, the truFreeze System, incorporating the reduced French Size, additional Marker Bands, 5-Pack unit boxes and updated Operator's Manual, IFU and Product Labels, is substantially equivalent to the predicate device.
Conclusion
Based on the comparison of labeling, technology and verification testing comparisons, the truFreeze device is substantially equivalent to the predicate device K161557.